
The latest edition of the Spanish Journal of Health Economics is available. For all of you interested in the development of regulations around biosimilars there is an interesting article on the subject (in Spanish).
Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
No comments:
Post a Comment